Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

Fig. 5Fig. 5

a. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Docetaxel (n = 122, 901 assessments) b. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Paclitaxel (n = 33, 245 assessments) c. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Cisplatin/Carboplatin (n = 80, 409 assessments) d. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Oxaliplatin (n = 28, 200 assessments) e. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Carboplatin+Docetaxel (n = 29, 274 assessments) f. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Carboplatin+Paclitaxel (n = 49, 357 assessments)

Back to article page